tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Barcus, 36 are a BUY (94.74%), 2 are a HOLD (5.26%).
Analyst Matthew Barcus, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 63.64% that have a potential upside of 73.66% achieved within 298 days.
Matthew Barcus’s has documented 71 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on QURE, Uniqure NV at 22-Jun-2023.
Analyst best performing recommendations are on IMVT (IMMUNOVANT).
The best stock recommendation documented was for IMVT (IMMUNOVANT) at 9/29/2022. The price target of $12 was fulfilled within 36 days with a profit of $6.62 (123.05%) receiving and performance score of 34.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Feb-2026
$40
$23.53 (142.87%)
$40
1 months 13 days ago
(10-Sep-2026)
0/2 (0%)
$15.03 (60.19%)
Buy Since 18-Dec-2023
$35
$18.53 (112.51%)
$31
2 months 11 days ago
(12-Aug-2026)
2/10 (20%)
$7.01 (25.04%)
14
Buy Since 02-Apr-2025
$30
$13.53 (82.15%)
$32
7 months 18 days ago
(04-Mar-2026)
1/3 (33.33%)
$9.05 (43.20%)
258
Buy Since 08-Nov-2024
$30
$10.04 (50.30%)
$33
7 months 19 days ago
(04-Mar-2026)
0/4 (0%)
$7.48 (33.21%)
Buy Since 05-Sep-2025
$36
$16.04 (80.36%)
$33
7 months 19 days ago
(04-Mar-2026)
1/3 (33.33%)
$13.48 (59.86%)
150
What Year was the first public recommendation made by Matthew Barcus?
